Psilocybin as a Novel Therapy for Residual Anhedonia

Summary

The primary objective is to evaluate whether a single dose of psilocybin (25 mg), compared to placebo, can restore fronto-striatal reward circuit function and thereby improve anhedonia and emotional blunting in individuals with residual symptoms despite ongoing SSRI or SNRI treatment. This will be assessed using precision functional mapping (PFM), task-based fMRI, and clinical rating scales (DARS).

Timeline

Start

2026-07

Primary completion

2030-08-01

Completion

2030-09-30

Drugs

Indications